StockNews.com Downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) to Buy

Regeneron Pharmaceuticals (NASDAQ:REGN) was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating in a research report issued to clients and investors on Monday.

A number of other analysts also recently commented on the company. TD Cowen boosted their target price on Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the stock a “buy” rating in a research report on Tuesday, July 23rd. Guggenheim boosted their target price on Regeneron Pharmaceuticals from $1,180.00 to $1,300.00 and gave the stock a “buy” rating in a research report on Friday, August 2nd. Leerink Partnrs downgraded Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 24th. Leerink Partners reiterated a “market perform” rating and set a $1,077.00 target price (down from $1,175.00) on shares of Regeneron Pharmaceuticals in a research report on Tuesday, September 24th. Finally, Evercore ISI reduced their price objective on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating on the stock in a research report on Thursday, October 24th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and seventeen have given a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $1,097.25.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ:REGN traded down $14.76 during trading on Monday, reaching $828.84. The company had a trading volume of 733,389 shares, compared to its average volume of 518,704. The stock’s fifty day moving average price is $1,051.02 and its 200 day moving average price is $1,040.40. Regeneron Pharmaceuticals has a fifty-two week low of $783.57 and a fifty-two week high of $1,211.20. The firm has a market capitalization of $91.37 billion, a price-to-earnings ratio of 20.51, a price-to-earnings-growth ratio of 2.88 and a beta of 0.15. The company has a debt-to-equity ratio of 0.09, a current ratio of 5.99 and a quick ratio of 4.62.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported $11.56 earnings per share for the quarter, topping analysts’ consensus estimates of $8.93 by $2.63. Regeneron Pharmaceuticals had a return on equity of 16.88% and a net margin of 33.61%. The firm had revenue of $3.55 billion for the quarter, compared to analyst estimates of $3.38 billion. During the same quarter in the prior year, the company posted $8.79 earnings per share. Regeneron Pharmaceuticals’s quarterly revenue was up 12.3% on a year-over-year basis. As a group, equities research analysts predict that Regeneron Pharmaceuticals will post 37.46 EPS for the current year.

Insider Activity

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at approximately $18,447,575.65. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the firm’s stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the completion of the sale, the chief financial officer now owns 15,305 shares in the company, valued at $18,447,575.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Jason Pitofsky sold 487 shares of the firm’s stock in a transaction that occurred on Wednesday, August 7th. The shares were sold at an average price of $1,070.00, for a total value of $521,090.00. Following the sale, the vice president now owns 4,204 shares of the company’s stock, valued at approximately $4,498,280. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 7.48% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of REGN. SteelPeak Wealth LLC increased its position in Regeneron Pharmaceuticals by 173.0% in the 2nd quarter. SteelPeak Wealth LLC now owns 1,092 shares of the biopharmaceutical company’s stock valued at $1,148,000 after acquiring an additional 692 shares during the period. Atria Investments Inc increased its position in Regeneron Pharmaceuticals by 12.2% in the 1st quarter. Atria Investments Inc now owns 8,657 shares of the biopharmaceutical company’s stock valued at $8,317,000 after acquiring an additional 941 shares during the period. Tri Locum Partners LP increased its position in Regeneron Pharmaceuticals by 104.5% in the 2nd quarter. Tri Locum Partners LP now owns 17,516 shares of the biopharmaceutical company’s stock valued at $18,410,000 after acquiring an additional 8,949 shares during the period. Tidal Investments LLC increased its position in Regeneron Pharmaceuticals by 16.8% in the 1st quarter. Tidal Investments LLC now owns 4,955 shares of the biopharmaceutical company’s stock valued at $4,774,000 after acquiring an additional 711 shares during the period. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Regeneron Pharmaceuticals during the 1st quarter valued at $1,232,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.